Nature Communications (May 2022)

Molecular basis for inhibiting human glucose transporters by exofacial inhibitors

  • Nan Wang,
  • Shuo Zhang,
  • Yafei Yuan,
  • Hanwen Xu,
  • Elisabeth Defossa,
  • Hans Matter,
  • Melissa Besenius,
  • Volker Derdau,
  • Matthias Dreyer,
  • Nis Halland,
  • Kaihui Hu He,
  • Stefan Petry,
  • Michael Podeschwa,
  • Norbert Tennagels,
  • Xin Jiang,
  • Nieng Yan

DOI
https://doi.org/10.1038/s41467-022-30326-3
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 10

Abstract

Read online

Human glucose transporters (GLUTs), particularly GLUT1 and GLUT3, are potential anticancer therapy targets. Here, Nan Wang et al. use an engineered GLUT 3 variant to identify an exofacial GLUT3 inhibitor, SA47, and elucidate the drug’s inhibitory mechanism.